Drug Profile
Finerenone - Bayer HealthCare Pharmaceuticals
Alternative Names: Kerendia; BAY-94-8862; KERENDIA; KerendiaLatest Information Update: 25 Dec 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies
- Phase III Chronic heart failure; Heart failure; Renal failure
Most Recent Events
- 11 Nov 2023 Pharmacodynamics data from preclinical trial in Renal failure presented at the American Heart Association Scientific Sessions (AHA-2023)
- 11 Nov 2023 The pooled biomarker analysis data form phase III FIGARO-DKD and FIDELIO-DKD trials in Type-2 diabetes mellitus and Chronic Kidney Disease was presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
- 02 Oct 2023 Efficacy and adverse events data from phase III FIGARO-DKD trial in Diabetic nephropathies presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)